MALVERN, PA — Neuronetics Inc. (Nasdaq: STIM) granted 123,300 restricted stock units to 14 non-executive employees on Nov. 4, 2026, as employment incentives designed to support recruitment and retain personnel at the Malvern-based mental health technology company.
The equity awards were approved by Neuronetics’ Compensation Committee under Nasdaq Listing Rule 5635(c)(4), which permits qualifying equity compensation grants as an inducement to employment.
According to the company, the awards were issued under its 2020 Inducement Incentive Plan and are subject to continued employment through the applicable vesting dates.
Most of the restricted stock units will vest in three equal annual installments, beginning on the first anniversary of the grant date.
Two employees, Allison Manzer and Erin DiMarco, received additional awards with a different vesting schedule, beginning on the second anniversary and continuing in equal annual installments through the fourth anniversary.
Manzer received a combined 44,250 restricted stock units, consisting of an award of 29,250 units vesting over the first three years and an additional 15,000 units vesting between the second and fourth anniversaries.
DiMarco received 23,250 units, including 11,250 vesting over the first three years and 12,000 vesting between the second and fourth anniversaries.
Chad McCatherin, Jackie Fennelly, Ashley Reindel and Omar Saleh each received 9,000 restricted stock units.
Michael Rosenfield received 3,000 units.
Nicholas Trabucco, Maya McClain, Alexandra Germain, Pia Arellano, Egette Indelele, Alondra Pastrona and Giana Berrios each received 2,400 units.
The awards collectively represent 123,300 shares issuable upon vesting, subject to the conditions of the company’s incentive plan.
Neuronetics develops and markets NeuroStar Advanced Therapy, a transcranial magnetic stimulation system used in treating mental health conditions, including major depressive disorder.
The company also provides direct patient care through its Greenbrook network of interventional psychiatry clinics, which offer TMS and Spravato, an esketamine nasal spray used for certain forms of depression.
Neuronetics’ NeuroStar system has received U.S. Food and Drug Administration clearance for several indications, including major depressive disorder in adults, adjunctive treatment of obsessive-compulsive disorder in adults and adjunctive treatment of major depressive disorder in patients ages 15 to 21.
The stock awards establish multiyear vesting requirements for the newly hired employees, linking their equity compensation to continued service with Neuronetics.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.